Aurobindo Pharma announced that the United States Food and Drug Administration US FDA conducted its pre-approval inspection PAI and GMP inspection from 22 August to 26 August 2022 of Unit at Raleigh North Carolina USA owned by Aurolife Pharma LLC a wholly owned subsidiary of the company established for manufacturing MDI Metered Dose Inhalers and Derma products The Unit has filed 2 Derma products and 1 MDI product At the end of the inspection Aurolife has been issued a Form 483 with 1 observation and the observation is procedural in nature and there are no data integrity issues
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
